Senate introduces bill to restrict DXM sales to adults
WASHINGTON — Sens. Bob Casey, D.-Pa., and Lisa Murkowski, R-Alaska, on Wednesday introduced bipartisan legislation to prevent the abuse of cough syrup to get high by restricting the sale of products containing dextromethorphan to adults older than 18 years of age.
“By addressing easy access to purchasing cough syrup for teens, the main cause of the harmful trend of its abuse, my bill will help keep our children safe and lessen the strain cough syrup abuse has put on families, hospitals and law enforcement,” Casey said. “My common-sense legislation will prevent kids from purchasing a drug that has dangerous consequences when abused to get high, while also ensuring it is available to those with a legitimate need for it.”
“This legislation powerfully complements our ongoing educational initiatives to raise awareness about this troubling behavior,” CHPA president and CEO Scott Melville said. “It will give parents an additional tool to prevent abuse, while ensuring access for the millions of adults and families who responsibly use products containing DXM to relieve cough symptoms. We are extremely pleased to see such strong leadership from Sens. Casey and Murkowski and encourage Congress to pass this legislation.”
The active ingredient in many over-the-counter cough and cold medicines DXM is safe when taken as recommended, but 5% of teenagers report having intentionally taken large doses of DXM for effects that include hallucinations, confusion, blurred vision and loss of motor control. Sen. Casey’s Prevent Abuse of Cough Treatments Act will make it harder for teens to purchase the drug while still keeping cough medications accessible to those who use them for their intended purpose.
In addition to placing an age-restriction on the sale of DXM products, the PACT Act will ensure that only legitimate entities registered with the FDA or comparable state agencies can purchase raw, unfinished (bulk) dextromethorphan.
BioRx receives distribution rights to bleeding disorder drug
CINCINNATI — Days after its acquisition of Coagulife, specialty pharmacy provider BioRx has received limited distribution rights to a treatment for a bleeding disorder described as one of the rarest in the world.
The company, which specializes in treating bleeding disorders, said Wednesday that it had received the rights for Corifact (factor XIII concentrate [human]), a treatment made by CSL Behring for congenital Factor XIII deficiency. The drug received approval from the Food and Drug Administration in February 2011.
"We are very excited to begin serving the factor XIII patient population," BioRx co-founder Eric Hill said. "We are also pleased to expand our distribution partnership with CSL Behring in the bleeding disorders market."
Injectable filler technology inspires new Redermic [C] by La Roche-Posay
NEW YORK — Skin care company La Roche-Posay has developed the new Redermic [C], an anti-wrinkle firming moisturizer that was inspired by the growing popularity of injectable filler technology.
When treating skin-aging concerns, dermatologists implement a variety of procedures, treatments and ingredients. Influenced by minimally invasive hyaluronic acid filler injectables, La Roche-Posay incorporates fragmented hyaluronic acid. This smaller molecule size (versus other topical hyaluronic acid molecules) allows for better diffusion to help visibly plump the skin, the company stated.
Dermatologists also incorporate such collagen-building treatments as prescription-strength retinoids and antioxidant ingredients, like vitamins A, C and E. Redermic [C] contains 5% pure vitamin C, a powerful antioxidant known for its ability to help synthesize collagen and even minimize the appearance of wrinkles. Finally, the product includes mannose, a sugar molecule that smoothes the skin’s surface and evens tone by optimizing the interaction of skin and light.
“Aesthetic procedures have become one of the fastest-growing areas of dermatology, because more women want to look and feel younger with the added benefits of lower costs and shorter recovery time,” stated Dr. Dina Anderson. “Redermic [C] is an effective adjunct to use in conjunction with many minimally invasive procedures, like fillers, as a way to continue combating wrinkles over time.”
Redermic [C] has an ultra-rich, melt-in texture that leaves a nongreasy finish. Noncomedogenic, paraben-free, fragrance-free, dermatologist-tested and safe for sensitive and dry skin, it can be used in the morning and night on the face and neck.
Redermic [C] from La Roche-Posay has a suggested retail price of $53.95 for normal/combination, $53.95 for dry, $53.95 for UV and $43.95 for eyes. The line will be offered beginning in September at select physicians’ offices and select CVS/pharmacy, Ulta, Walgreens and Duane Reade locations.